Skip to main content

Advertisement

Table 1 Correlation between CMTM 5 expression and clinicopathological variables of 76 HCC patients

From: CMTM5 is downregulated and suppresses tumour growth in hepatocellular carcinoma through regulating PI3K-AKT signalling

Variables Cases (76) CMTM5 expression P value
High (17) Low (59)
Age (years)
 ≤ 50 47 12 (70.6%) 35 (59.3%) 0.572
 > 50 29 5 (29.4%) 24 (40.7%)
Gender
 Male 57 11 (64.7%) 46 (77.9%) 0.266
 Female 19 6 (35.3%) 13 (22.1%)
AFP (ng/mL)
 ≤ 20 35 7 (41.2%) 28 (47.5%) 0.647
 > 20 41 10 (58.8%) 31 (52.5%)
ALT (U/mL)
 ≤ 75 40 10 (58.8%) 30 (50.8%) 0.564
 > 75 36 7 (41.2%) 29 (49.2%)
GGT (U/mL)
 ≤ 45 43 11 (64.7%) 32 (54.2%) 0.443
 > 45 33 6 (35.3%) 27 (45.8%)
Tumor size (diameter), cm
 ≤ 5 34 10 (58.8%) 24 (40.7%) 0.185
 > 5 42 7 (41.2%) 35 (59.3%)
Tumor multiplicity
 Single 53 12 (70.6%) 41 (69.5%) 0.931
 Multiple 23 5 (29.4%) 18 (30.5%)
Vascular invasion
 Yes 20 5 (29.4%) 15 (25.4%) 0.742
 No 56 12 (70.6%) 44 (74.6%)
Tumor differentiation
 I–II 57 16 (94.1%) 41 (69.5%) 0.039*
 III–IV 19 1 (5.9%) 18 (30.5%)
TNM stage
 I 41 14 (82.4%) 27 (45.8%) 0.028*
 II 25 2 (11.7%) 23 (38.9%)
 III 10 1 (5.9%) 9 (15.3%)
  1. P < 0.05